4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 4.2% – Here’s What Happened

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) traded down 4.2% during trading on Wednesday . The company traded as low as $11.03 and last traded at $11.0390. 88,569 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 849,719 shares. The stock had previously closed at $11.52.

Analysts Set New Price Targets

Several research firms have issued reports on FDMT. Chardan Capital restated a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday. Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Barclays decreased their target price on 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. Leerink Partners reaffirmed an “outperform” rating and set a $17.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st. Finally, Morgan Stanley upgraded 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research note on Friday, November 7th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $28.70.

4D Molecular Therapeutics Trading Down 0.1%

The company has a market capitalization of $495.93 million, a PE ratio of -2.31 and a beta of 2.96. The firm has a 50 day simple moving average of $10.68 and a two-hundred day simple moving average of $7.47.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Monday, November 10th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.01. The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.40 million. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%. Research analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Insider Buying and Selling at 4D Molecular Therapeutics

In other news, insider Scott Bizily sold 2,678 shares of the business’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $12.00, for a total transaction of $32,136.00. Following the transaction, the insider directly owned 3,594 shares in the company, valued at $43,128. The trade was a 42.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 12,398 shares of company stock valued at $127,236 over the last quarter. 9.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of FDMT. Dynamic Technology Lab Private Ltd acquired a new stake in shares of 4D Molecular Therapeutics during the 1st quarter valued at approximately $39,000. Wexford Capital LP purchased a new stake in 4D Molecular Therapeutics in the 3rd quarter worth approximately $41,000. Los Angeles Capital Management LLC purchased a new stake in shares of 4D Molecular Therapeutics in the second quarter valued at $42,000. Quadrature Capital Ltd acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter valued at about $42,000. Finally, Farther Finance Advisors LLC increased its position in 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after purchasing an additional 2,674 shares during the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.